Advertisement
Research ArticleCellular and Molecular

Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

Flavio Solca, Goeran Dahl, Andreas Zoephel, Gerd Bader, Michael Sanderson, Christian Klein, Oliver Kraemer, Frank Himmelsbach, Eric Haaksma and Guenther R. Adolf
Journal of Pharmacology and Experimental Therapeutics November 2012, 343 (2) 342-350; DOI: https://doi.org/10.1124/jpet.112.197756
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleCellular and Molecular

Afatinib, an Irreversible Inhibitor of EGFR, HER2, and ErbB4

Flavio Solca, Goeran Dahl, Andreas Zoephel, Gerd Bader, Michael Sanderson, Christian Klein, Oliver Kraemer, Frank Himmelsbach, Eric Haaksma and Guenther R. Adolf
Journal of Pharmacology and Experimental Therapeutics November 1, 2012, 343 (2) 342-350; DOI: https://doi.org/10.1124/jpet.112.197756
Reddit logo Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement